secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scorpius Holdings, Inc. (—)
CIK:        0001476963
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001558370-23-019741
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 3.03, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NightHawk Biosciences divests Elusys to CEO-controlled buyer; $500k upfront, $2.25M note, royalty
--------------------------------------------------------------------------------

- Buyer paid $500k cash and assumed ~$40M in liabilities; receives Elusys equity and 'NightHawk' name.
- Convertible note: $2.25M at 1% interest, matures in 1 year; conversion price set at 110% of 7-day VWAP.
- NightHawk to receive 3% royalty on ANTHIM (anthrax antitoxin) sales through June 2031, with $5M minimum by 2028.
- Post-transaction, NightHawk expects to eliminate $40M in contractual obligations and reduce annual expenses by $13M.
- CEO Jeffrey Wolf and CFO William Ostrander retain roles at NightHawk and also serve as officers of Buyer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/0001558370-23-019741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1476963/000155837023019741/nhwk-20231211x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer